CAS 60940-34-3 Ebselen - Analytical Products / Alfa Chemistry

CAT	AP60940343
CAS	60940-34-3
Structure
MDL Number	MFCD00210937
Molecular Weight	274.18
InChI Key	DYEFUKCXAQOFHX-UHFFFAOYSA-N

Description	cysteine modifier
Size	25MG, 100MG
Storage Conditions	2-8°C

Ebselen Rescues Oxidative-Stress-Suppressed Osteogenic Differentiation of Bone-Marrow-Derived Mesenchymal Stem Cells via an Antioxidant Effect and the PI3K/Akt Pathway

Yiming Li, Guanhui Chen, Yi He, Xiliu Zhang, Binghui Zeng, Chao Wang, Chen Yi, Dongsheng Yu

J Trace Elem Med Biol. 2019 Sep;55:64-70.

PMID: 31345368

Ebselen, a Promising Antioxidant Drug: Mechanisms of Action and Targets of Biological Pathways

Gajendra Kumar Azad, Raghuvir S Tomar

Mol Biol Rep. 2014 Aug;41(8):4865-79.

PMID: 24867080

Identification of Ebselen as a Potent Inhibitor of Insulin Degrading Enzyme by a Drug Repurposing Screening

Florence Leroux, Damien Bosc, Terence Beghyn, Paul Hermant, Sandrine Warenghem, Valérie Landry, Virginie Pottiez, Valentin Guillaume, Julie Charton, Adrien Herledan, Sarah Urata, Wenguang Liang, Li Sheng, etc.

Eur J Med Chem. 2019 Oct 1;179:557-566.

PMID: 31276900

The Cysteine-Reactive Small Molecule Ebselen Facilitates Effective SOD1 Maturation

Michael J Capper, Gareth S A Wright, Letizia Barbieri, Enrico Luchinat, Eleonora Mercatelli, Luke McAlary, Justin J Yerbury, Paul M O'Neill, Svetlana V Antonyuk, Lucia Banci, S Samar Hasnain

Nat Commun. 2018 Apr 27;9(1):1693.

PMID: 29703933

The Putative Lithium-Mimetic Ebselen Reduces Impulsivity in Rodent Models

Chris Barkus, Jacqueline-Marie N Ferland, Wendy K Adams, Grant C Churchill, Philip J Cowen, David M Bannerman, Robert D Rogers, Catharine A Winstanley, Trevor Sharp

J Psychopharmacol. 2018 Sep;32(9):1018-1026.

PMID: 29986609

* Products or Services Interested: Ebselen (60940-34-3)
* Your question
* Name
* Email
Verification Code

Case Study

Ebselen Used for the Covalent Modification and Destabilization of 14-3-3ζ Protein to Modulate Protein-Protein Interactions

Waløen, Kai, et al. Molecular Pharmacology 100.2 (2021): 155-169.

Ebselen, an organoselenium compound with antioxidant and thiol-reactive properties, is increasingly recognized for its therapeutic potential in cancer, neuropsychiatric disorders, and infectious diseases. In a recent study, ebselen was used to selectively modify and destabilize 14-3-3 proteins, a family of adaptor proteins involved in a wide array of signaling pathways and disease mechanisms.
Screening of 1,280 small molecules via differential scanning fluorimetry identified ebselen as a potent destabilizing ligand for 14-3-3 isoforms ζ, γ, η, and ε. Ebselen covalently modified cysteine residues in 14-3-3ζ through selenylsulfide bond formation, with C25 being the preferred binding site and C94 critically involved in thermal destabilization. This chemical modification disrupted the interaction between 14-3-3ζ and its phosphorylated client protein, tyrosine hydroxylase (pSer19-TH), revealing a functional impairment of the protein's chaperone activity.
At therapeutic concentrations, ebselen and its oxide analog also reduced cellular 14-3-3 levels via enhanced degradation through the ubiquitin-proteasome pathway. Behavioral assays in zebrafish treated with ebselen confirmed neurobehavioral changes resembling lithium treatment, supporting its role as a lithium-mimetic compound.
In conclusion, ebselen is used for the covalent modification of 14-3-3 proteins to disrupt protein-protein interaction networks, providing mechanistic insight into its pleiotropic biological effects and potential application as a molecular modulator in neuropsychiatric and oncologic drug development.

Ebselen Used for the Preparation of Redox-Responsive Coatings for Anti-Atherosclerotic Applications

Chen, Xinyi, et al. Colloids and Surfaces B: Biointerfaces 245 (2025): 114314.

Ebselen, a glutathione peroxidase (GPx) mimetic with potent redox activity, has emerged as a multifunctional agent for the treatment of oxidative stress-related vascular diseases. In this study, Ebselen was successfully incorporated into poly(trimethylene carbonate) (PTMC) matrices to fabricate redox-responsive coatings aimed at addressing atherosclerosis (AS) progression by mitigating reactive oxygen species (ROS) damage and restoring nitric oxide (NO) bioavailability.
The Ebselen-loaded PTMC coatings (designated PTMC5 and PTMC10, containing 5% and 10% Ebselen by mass, respectively) were prepared via solvent evaporation onto 316L stainless steel substrates. These coatings demonstrated an impressive ROS scavenging efficiency of up to 89%, while also catalytically generating NO at physiologically relevant levels (0.96-1.26 × 10⁻¹⁰ mol/cm²/min). Importantly, Ebselen enabled a redox cycle-based sustained release mechanism, continuously protecting vascular endothelial cells from oxidative injury.
The PTMC10 coating exhibited significantly reduced fibrotic encapsulation in vivo, with fibrous capsule thickness reduced to 47.7% of that seen in unmodified PTMC controls. Furthermore, the coatings maintained excellent hemocompatibility and cytocompatibility, promoting endothelialization while simultaneously inhibiting smooth muscle cell proliferation-critical for the prevention of restenosis.
In summary, Ebselen is used for the preparation of advanced redox-active PTMC coatings, offering a promising strategy for the development of next-generation cardiovascular stents targeting oxidative microenvironments in atherosclerosis.